Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $2.9 billion.

  • Novartis Ag's Free Cash Flow fell 3952.85% to $2.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $20.7 billion, marking a year-over-year increase of 899.13%. This contributed to the annual value of $20.7 billion for FY2025, which is 899.13% up from last year.
  • Per Novartis Ag's latest filing, its Free Cash Flow stood at $2.9 billion for Q4 2025, which was down 3952.85% from $6.9 billion recorded in Q3 2025.
  • Novartis Ag's 5-year Free Cash Flow high stood at $7.0 billion for Q2 2025, and its period low was $1.9 billion during Q1 2022.
  • Moreover, its 5-year median value for Free Cash Flow was $4.4 billion (2021), whereas its average is $4.3 billion.
  • As far as peak fluctuations go, Novartis Ag's Free Cash Flow soared by 6088.72% in 2024, and later tumbled by 3952.85% in 2025.
  • Quarter analysis of 5 years shows Novartis Ag's Free Cash Flow stood at $4.3 billion in 2021, then grew by 1.68% to $4.4 billion in 2022, then tumbled by 33.14% to $3.0 billion in 2023, then skyrocketed by 60.89% to $4.8 billion in 2024, then tumbled by 39.53% to $2.9 billion in 2025.
  • Its Free Cash Flow was $2.9 billion in Q4 2025, compared to $6.9 billion in Q3 2025 and $7.0 billion in Q2 2025.